Triclabendazole resistant fasciola hepatica: pharmacokinetic and efficacy assessments of a drug combined treatment.

CEBALLOS, L; ALVAREZ, L; MORENO, L; LANUSSE, C

Buenos Aires. Argentina

Congreso; XXXIX Reunion Anual de la Asociación Argentina de Farmacología Experimantal.; 2007

TRICLABENDAZOLE RESISTANT FASCIOLA HEPATICA: PHARMACOKINETIC AND EFFICACY ASSESSMENTS OF A DRUG COMBINED TREATMENT  Ceballos, L., Alvarez, L., Moreno, L., Lanusse, C. Laboratorio de Farmacología, FCV, UNCPBA.; CONICET. E-mail: ceballos@vet.unicen.edu.ar The altered drug influx/efflux and enhanced metabolic capacity identified in triclabendazole (TCBZ)-resistant Fasciola hepatica  contributes to the development of resistance to TCBZ. The aim of this work was to evaluate the pharmacokinetics (PK) and clinical efficacy (CE) of TCBZ administered alone or co-administered with ivermectin (IVM, drug efflux inhibitor) and methimazole (MTZ, metabolic inhibitor) in TCBZ-resistant F. hepatica parasitized sheep. Sheep infected with TCBZ-resistant F. hepatica were divided into three groups (n= 4): untreated control, TCBZ-treated and TCBZ+IVM+MTZ treated sheep. Plasma samples were collected (PK study) and analysed by HPLC. In the CE study, the animals were sacrificed at 15 days post-treatment to evaluate the comparative efficacy against TCBZ-resistant F. hepatica. The presence of IVM and MTZ did not affect the plasma PK behaviour of TCBZ metabolites. The combined drug treatment was not sufficient to enhance the poor efficacy of TCBZ against resistant F. hepatica.  Finally, the enhancement of TCBZ concentrations in F. hepatica induced by both IVM and MTZ in ex vivo assays, did not reach a measurable effect under the current in vivo experimental conditions